PC
JAZZ icon

Paulson & Co’s Jazz Pharmaceuticals JAZZ Stock Holding History

Paulson & Co’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-963,000
Closed -$88.6M – 90
2013
Q3 		$88.6M Hold
963,000
– – 0.57% 43
2013
Q2 		$66.2M Buy
+963,000
New +$58.9M 0.47% 49

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Paulson & Co's JAZZ Position: Q4 2013 in Review

Paulson & Co sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2013, closing a stake of 963,000 shares — an estimated $88.6M sold.

Paulson & Co first reported a position in JAZZ in Q2 2013 and held it in 2 quarters. The position peaked at $88.6M in Q3 2013. 280 funds tracked by Wall St. Rank hold JAZZ as of Q4 2013.

  • Paulson & Co reported no remaining Jazz Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Paulson & Co sold 963,000 Jazz Pharmaceuticals shares in Q4 2013, an estimated $88.6M.
  • Paulson & Co first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Paulson & Co's Jazz Pharmaceuticals position peaked at $88.6M in Q3 2013.
  • 280 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2013.

Based on Paulson & Co's 13F filing for Q4 2013, filed 14 Feb 2014.